Biotech | April 12, 2022
ReiThera and Exothera collaborate to develop large-scale, low cost per dose vaccine
Collaboration awarded €3 million grant by the Bill & Melinda Gates Foundation
Collaboration awarded €3 million grant by the Bill & Melinda Gates Foundation
Both mRNA-1020 and mRNA-1030 target hemagglutinin and neuraminidase antigens, two major influenza surface glycoproteins that are essential across the viral life cycle
The recombinant nanoparticle-based rabies G protein vaccine is prepared using virus-like particle technology.
Veeda Clinical Research will submit data in an application for Emergency Use Authorisation
CanSinoBIO will continue to focus on developing a variety of innovative preventive vaccines in its diversified product pipeline with proprietary technologies, including the inhaled version of its COVID-19 vaccine, Convidecia
Supply increase to help meet growing global demand
BVX-0922 to target colorectal cancer under investigator-sponsored IND
The companies are now preparing to initiate a Phase 1 trial to assess the safety and immunogenicity of BLB-201 in healthy volunteers
Under the agreement, Technology Development Board and Bharat Biotech have pledged the support of Rs.200 crore each to create a continuous corpus of Rs.400 crores for the project
U.S. NIAID-sponsored trial will evaluate heterologous booster regimens, including NVX-CoV2373, after primary series with current USFDA approved or emergency use authorized-vaccines
Subscribe To Our Newsletter & Stay Updated
